| 2026-07-30 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-30 | Press release | Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-07-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-30 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-30 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-29 | Deck | Phathom Pharmaceuticals – Corporate Overview – July 2026 |
| 2026-07-20 | Press release | Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30 |
| 2026-06-23 | Press release | Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vo |
| 2026-06-23 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-07 | Press release | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results |
| 2026-06-06 | Press release | Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance (Corrected) |
| 2026-05-22 | Press release | Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 2026-05-21 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-20 | Press release | Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meet |
| 2026-05-01 | Press release | Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting |
| 2026-04-30 | Press release | Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-04-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-30 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-29 | Deck | FIRST QUARTER 2026 EARNINGS CONFERENCE CALL |
| 2026-04-20 | Press release | Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30 |
| 2026-04-07 | Proxy | Definitive proxy statement |
| 2026-04-06 | Press release | Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 2026-03-02 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-26 | Press release | Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance |
| 2026-02-26 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-26 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-25 | Deck | FOURTH QUARTER & FULL YEAR 2025 EARNINGS CONFERENCE CALL |
| 2026-02-23 | Press release | Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 2026-02-17 | Press release | Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026 |
| 2026-02-05 | Press release | Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 |
| 2026-01-08 | 8-K | Form 8-K, Item 8.01 |
| 2026-01-07 | Press release | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results |
| 2026-01-07 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-04 | 8-K | Form 8-K, Item 8.01 |
| 2025-10-30 | 8-K | Form 8-K, Item 2.02 results |
| 2025-10-30 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-29 | Deck | THIRD QUARTER 2025 EARNINGS CONFERENCE CALL |
| 2025-10-27 | 8-K | Form 8-K, Item 8.01 |
| 2025-10-06 | 8-K | Form 8-K, Item 5.02 |
| 2025-08-07 | 8-K | Form 8-K, Item 2.02 results |